IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack
NCT06139328
Recruiting
This study is open to adults aged 18 and over who have just had a heart attack. The purpose of this study is to find out whether a medicine called BI 765845 helps people who have had a heart attack. The investigators also want to test how well different doses of BI 765845 work and how they are tolerated by people who have had a heart attack. Participants are randomly assigned to receive either BI 765845 or placebo. Placebo treatments look like BI 765845 treatments but do not contain any medicin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: University of Arizona, Tucson, Arizona +103 locations
Conditions: Myocardial Infarction
Register for Updates
FORWARD CAD IDE Study
NCT06662500
Recruiting
The FORWARD CAD IDE Study is a Prospective, Multicenter, Single-Arm, Investigational Device Exemption (IDE) Study conducted to assess the safety and effectiveness of the Shockwave Intravascular Lithotripsy (IVL) System with the Javelin Coronary IVL Catheter for the treatment of calcified, stenotic de novo coronary artery lesions prior to stenting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/18/2025
Locations: Scripps Health, La Jolla, California +23 locations
Conditions: Coronary Arterial Disease (CAD)
Register for Updates
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
NCT05947955
Recruiting
BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN plus standard of care (SOC) in subjects with moderate-to-severe ARDS (P/F ratio ≤150) due to pneumonia or other infections. Potential subjects hospitalized with pneumonia or other infections are to be screened within 24 hours of diagnosis of ARDS.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/17/2025
Locations: University of California Irvine Medical Center, Irvine, California +66 locations
Conditions: Acute Respiratory Distress Syndrome, Infections
Register for Updates
Phase Ib/IIa Trial With AC01 in Patients With HFrEF
NCT05642507
Recruiting
This is a randomized, double-blind, placebo-controlled two-part study with a multiple escalating dose phase followed by a cohort expansion phase to assess safety, tolerability, pharmacokinetics and pharmacodynamics of AC01 in patients with heart failure with reduced ejection fraction (HFrEF).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/16/2025
Locations: Spedali Civilia di Brescia, Brescia, Not set +12 locations
Conditions: Heart Failure With Reduced Ejection Fraction
Register for Updates
Pavlik Harness Treatment vs Monitoring for Treatment of Developmental Dysplasia of the Hip (DDH) in Babies Diagnosed With Graf Type 2 Hips
NCT07111858
Recruiting
Developmental Dysplasia of the Hip (DDH) is thoroughly manageable if treated correctly. While the standard treatment is using a Pavlik harness, there is not enough research regarding those patients who have stable but immature Graf type 2b and 2c hips and whether a harness is needed. At Maidstone and Tunbridge Wells NHS Trust, all babies who present with Graf type 2b and 2c hip dysplasia are treated using a Pavlik harness, which is worn 24 hours a day for up to 12 weeks. Although the harness is... Read More
Gender:
ALL
Ages:
Between 0 weeks and 16 weeks
Trial Updated:
08/15/2025
Locations: Maidstone and Tunbridge Wells NHS trust, Tunbridge Wells, Not set
Conditions: Developmental Hip Dysplasia
Register for Updates
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764
Recruiting
The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Arkansas Urology, Little Rock, Arkansas +122 locations
Conditions: Non-Muscle Invasive Bladder Neoplasms
Register for Updates
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
NCT04159103
Recruiting
This 3-part, Phase 1/2 study is designed to characterize the safety, tolerability, and pharmacological activity (as assessed by biomarker measurements) and to determine the selected dose of mRNA-3927 in participants with genetically confirmed propionic acidemia (PA). After establishing a dose with an acceptable safety and pharmacodynamic (PD) response for participants ≥1 year of age in Part 1, participants will be enrolled in Part 2 (which will serve as the pivotal study) to allow for determinat... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/15/2025
Locations: UCSD Altman Clinical and Transalational Research Institute Building, Los Angeles, California +34 locations
Conditions: Propionic Acidemia
Register for Updates
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203
Recruiting
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
Gender:
ALL
Ages:
Between 60 years and 85 years
Trial Updated:
08/15/2025
Locations: Fullerton Neurology and Headache Center, Fullerton, California +115 locations
Conditions: Alzheimer's Disease
Register for Updates
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028
Recruiting
B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-525 as a monotherapy. ABBV-525 is an investigational drug being developed for the treatment of B-Cell Malignancies. Study doctors put the participants in groups called treatment arms. Participants will receive ABBV-525 at different doses. Approximately 150 adult... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: University of California Los Angeles /ID# 246357, Los Angeles, California +33 locations
Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
Register for Updates
Validation of a Novel Functional Food Designed to Meet the Nutritional Needs of People Living With Parkinson's Disease
NCT06697626
Recruiting
Constipation is a common complication and non-motor symptom of Parkinson's disease (PD) and affects up to 80% of people with PD. It is in fact within the non-motor symptoms that nutrition and dietetic intervention could have the greatest impact. Research suggests that increasing the amount of fibre in the diet could help to alleviate the effects of constipation. Inulin is a type of fibre widely found in a variety of vegetables, and recent studies have shown that inulin can improve constipation i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Human Intervention Studies Unit, Ulster University, Coleraine, County Londonderry
Conditions: Constipation, Parkinson Disease
Register for Updates
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
NCT06440967
Recruiting
One of the standard treatments for women with breast cancer is hormone therapy, but this treatment can cause hot flashes. Hormone replacement therapy, or HRT, is most often prescribed for hot flashes for women in menopause but cannot be given to women on hormone therapy for breast cancer. Fezolinetant, an alternative to HRT, treats hot flashes for women in menopause. As hot flashes happen in the same way for women on hormone therapy for breast cancer, fezolinetant could help these women. In this... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Site CA15002, Montreal, Quebec +91 locations
Conditions: Hot Flashes
Register for Updates
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069
Recruiting
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Sarah Cannon Research Institute at HealthOne, Denver, Colorado +23 locations
Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Register for Updates